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Background: This manuscript describes the development of a novel synthetic immunotherapy (HIV-v) composed of
four multi-epitope polypeptides targeting conserved regions in the Nef, Rev, Vif and Vpr viral proteins.
Immunogenicity and cytotoxicity of HIV-v are discussed.
Methods: Short conserved T-cell multi-epitope regions were identified in silico in the HIV proteome. The
immunogenicity of the identified HIV-v polypeptides was assessed in vivo by immunisation of C57BLK6 mice
transgenic for HLA-A*0201. Splenocytes from immunised animals were exposed in vitro to soluble HIV-v
polypeptides or to syngeneic (T1) or allogeneic (Jurkat) cells transfected with these polypeptides. Specific T-cell
reactivity was assessed by cell-based IFN-γ ELISA. Virus specific CD3 + CD8+ IFN-γ+ recall responses were also
determined by flow cytometry following in vitro exposure of splenocytes from immunised mice to syngeneic (T1)
and allogeneic (H9) cells infected with HIV-1 strain IIIB. HIV-v specific antibodies were quantified by ELISA whilst
antibody mediated anti-viral immunotherapeutic effect on T1 cells infected with a laboratory adapted and a
primary isolate of the HIV-1 virus was assessed in a LDH-based complement mediated lysis assay.
Results: HIV-v elicited antigen-specific IgG and IFN−γ responses against the synthetic polypeptides in the
formulation. HIV-v specific T cells recognised polypeptides presented either as soluble antigen or complexed to
HLA-A*0201 following natural processing and presentation by syngeneic human T1 cells. Moreover, the CD3 + CD8+
component of the response recognised syngeneic T1 cells naturally infected with HIV-1 in a virus-specific and MHC
restricted-manner. The HIV-v specific IgG response was also able to recognise human T1 cells naturally infected with
HIV-1 and induce cell death through classic activation of complement.
Conclusions: HIV-v induces a vaccine-specific type I immune response characterised by activation of effector CD8+ T
cell and antibody responses that recognise and kill human cell lines naturally infected with a laboratory adapted and a
primary isolate of the HIV-1 virus. The data supports the hypothesis that alternative HIV protein targets can be
effectively used to prime both cellular and antibody immune responses of clinical value in the prevention and
treatment of HIV infection.
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Human Immunodeficiency virus (HIV) is the causative
agent of AIDS. Worldwide, 25 million patients have died
so far and over 34 million people are currently infected.
Combined antiretroviral therapy has transformed the
treatment of HIV/AIDS and extended patients’ life-
expectancy. However, the long term-nature of this treat-
ment is associated with severe toxic side-effects, limited
compliance, development of resistance and high cost
[1-3]. The only hope to control the continuous spread
of HIV is to develop a vaccine or therapy that it is not
only effective but affordable. In 2011 only 54% out of
the 14.8 million people eligible for antiretroviral therapy
were receiving it. The UNAIDS estimates that $6.8 billion
a year will be required by 2015 to ensure access to treat-
ment, care and support for 15 million people living with
HIV/AIDS [4].
Despite the urgent need and the global scientific ef-
forts, a vaccine to prevent HIV infection remains elusive
due to the high diversity of the virus, its ability to evade
the immune response and the lack of animal models in
which to test the efficacy of the vaccine [5]. Attempts at
developing prophylactic and therapeutic vaccines have
been made using life attenuated or inactivated virus, or
delivering HIV antigens as DNA vaccines or within viral
vectors to induce a cytotoxic T cell response and/or a
neutralising antibody response [5,6]. Preventative and
therapeutic peptide vaccines against HIV are a safe and
low cost alternative to anti-retroviral drugs and conven-
tional vaccines. The focus has been to identify short con-
served regions within the viral protein sequences, from
as little as five conserved aminoacids in the highly vari-
able Env gp160 protein [7] to single longer multiepitope
peptides within Oyi, a Tat variant found in HIV African
patients that did not progress to AIDS [8]. Others have
selected multiepitope peptides derived from several viral
proteins (Env, Gag and Nef ) [9]. However, the reality
remains that despite encouraging results in animal
models [8,10,11], the immunogenicity of peptide vac-
cines in humans trials remains modest [9,12] highlight-
ing the lack of correlation between the animal models
and human trials.
Over the last 20 years most HIV candidate vaccines
have exploited the immune responses naturally developed
against specific viral antigens during HIV infection. These
included antibody responses against Env [13-16] or more
recently, cellular immune responses to Tat and Nef [17,18].
The findings of the RV144 trial, in which a combined regi-
men of T and B cell vaccines was modestly effective in
preventing HIV infection [19], suggest that targeting both
antibody and cellular immunity against HIV might consti-
tute a better approach to induce protection, particularly
if, as suggested elsewhere [20], this immunity is targeted
to conserved regions within the HIV proteome.In this report, we describe a novel candidate immuno-
therapy (HIV-v), containing four synthetic polypeptides
derived from conserved immunoreactive regions of three
accessory proteins Vif, Vpr, Nef and the regulatory protein
Rev. The vaccine was prepared in Montanide ISA-51, a
water-in-oil adjuvant that potentiates the immunogenicity
of the peptide preparation. We provide evidence that
HIV-v induces specific CD8+ T cell and IgG responses
capable of recognising and killing a human cell line
infected with a laboratory adapted and a primary isolate
of the HIV-1 virus.
Results and discussion
Polypeptide selection
A major hurdle in HIV immunotherapy development is
viral sequence variability [21]. The aim of the analysis
was to identify highly conserved domains, containing a
high number of in silico predicted T cell epitopes, within
HIV proteins. It was not our aim to identify highly con-
served HIV proteins towards which high frequency nat-
ural immune responses are directed during infection.
Protein sequences from HIV-1 and HIV-2 strains were
included in the analysis since our aim was to develop a
universal immunotherapy against HIV virus. Inclusion of
HIV-2 sequences could alter the degree of protein se-
quence conservation found by others who limited their
analysis to HIV-1 sequences. Despite the current high
conservation shared amongst HIV-2 strains and the
lesser pathogenicity compared to HIV-1 strains, HIV-2
virus should be carefully monitored after reports of faster
evolution of Env proteins in patients infected with HIV-2
than those infected with HIV-1 [22]. These results sug-
gested that the HIV-2 virus has the potential to become
more pathogenic in the future due to mutations in its
genetic material.
The variability of the HIV proteome has been exten-
sively studied by many groups [23-25]. These studies have
regularly identified Gag, Pol and Tat as the most con-
served HIV proteins, and these sequences together with
envelope glycoprotein sequences (Env) are the most com-
monly incorporated in candidate vaccines [13-19]. In our
analysis, we defined highly conserved domains as regions
between 20–50 aa where every single consecutive aa was
present in ≥70% of the HIV isolate population analysed.
Others have used different parameters to determine
conservation, such as aminoacid entropy [26].
Domains containing a high number of in silico predicted
T cell epitopes were defined as those which, according to
our in-house algorithm, contained at least 5 CD8+ T cell
epitopes for HLA alleles A*02, A*24, B*27 and B*35. These
are the most frequently reported HLA Class I alleles
worldwide [27,28]. We have used this same approach to
select the targets for a novel universal Influenza vaccine
(FLU-v), which has successfully completed Phase I / II
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from those reported in other studies, but those studies
also used a different range of HLAs (e.g. as B*07 and
A*02, A*11, A*30, etc.) and usually sought to identify
naturally occurring immune responses [31].
The results of some of our analysis combining aminoacid
conservation and prediction of T-cell epitopes are illus-
trated in Figure 1. Consistent with the existing literature,
proteins such as Pol and Tat (Figure 1) were found to
be highly conserved overall and predicted to be mostFigure 1 Sequence variability and CD8+ CTL epitope density in HIV p
proteins. Multiple sequence analysis of all HIV-1 and −2 isolates sequences
Taxonomy database (January 2006) were carried out using CLUSTALW. The
sequence of selected HIV proteins. The dotted black line represents the mi
within any given region to be considered as conserved. The location of po
algorithm. The lower red line represents the number of identified 9-mer ep
aminoacid falls at the indicated position within the analysed protein.immunogenic. Nonetheless, their conserved regions
were rejected due to length (i.e. <20-50 aa), lack of re-
active epitopes (i.e. <5), potential for cross-reactivity
with other known human or rodent protein sequences
(high similarity in at least 7 consecutive aminoacids),
and/or unfeasible large-scale synthesis by Fmoc chem-
istry. Interestingly, we did not encounter these prob-
lems with the Vif, Vpr, Rev and Nef proteins (Figure 1).
These proteins, despite in several cases having lower
levels of conservation, all contained at least one highlyroteins. Sequence variability and CD8+ CTL epitope density in HIV
available at the National Centre for Biotechnology Information (NCBI)
upper black line represents the % aminoacid conservation along the
nimum conservation threshold (70%) required for the aminoacids
tential CD8+ CTL epitopes was identified in silico using a proprietary
itopes, in the context of HLA A-02, *A-24, *B-27 and *B35, whose first
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least 5 CD8+ T cell epitopes, sharing no similarity with
either human or rodent sequences and being amenable
to easy large-scale manufacture by F-moc chemistry.
We must point out that our proprietary algorithm
identifies and ranks T-cell epitopes within a given protein
sequence based on the analysis of the structural affinity of
a peptide for a given HLA allele and the potential reactiv-
ity of this complex to T cells. Many of the highest ranked
epitopes predicted by our algorithm have already been
described experimentally and were found within pro-
teins such as Tat and Pol. However, many of these epi-
topes fell within regions of high variability, probably
reflecting immune selective pressure. In contrast, many
of the T-cell epitopes predicted in Vif, Vpr, Rev and Nef
were ranked as sub-dominant by our algorithm, but they
were found within regions of reduced sequence variabil-
ity. Typically, the bulk of the CD8+ T-cell response is
directed to a limited number of immunodominant epi-
topes [32], and it is probably due to the low frequency
of CD8+ effectors to most of the epitopes in Vif, Vpr,
Rev and Nef in infected humans that not all these epi-
topes have been described experimentally. Nonetheless,
immunodominance is not a pre-requisite for vaccine
efficacy, and subdominant epitopes have already been
proposed as candidate targets for therapeutic vaccin-
ation against HIV [33,34] and shown to constitute effect-
ive vaccines for the control of respiratory viral infections
[35,36].
Based on these results, the four identified regions within
the regulatory protein Rev and accessory proteins Vif, Nef
and Vpr were selected as target sequences for our final
vaccine formulation, HIV-v (Table 1). These four proteins
are involved in viral replication, immune downregulation












aAmino acid location for each sequence is referenced to the consensus sequence d
of aminoacids. Marked with (*) are the aminoacid sequences component of NRP-v.have been previously described in Vif [42,43], Nef [44-46],
Vpr [47] and Rev [48].
Immunogenicity of selected polypeptides
To establish whether HIV-v could induce an antigen
specific cellular response within the context of human
MHC, C57BLK/6 mice transgenic for Class I HLA-
A*0201 were immunised with either HIV-v or a non-
relevant polypeptide formulation (NRP-v). These mice
express HLA-A2.1 in spleen, bone marrow and thymus
and have been used as a model for the identification of
HLA-A2.1 restricted CD8+ CTL epitopes in other virus
[49]. HIV-v was prepared as an emulsion prior injection
with adjuvant Montanide ISA-51. A preliminary study
concluded that adjuvant Montanide ISA-51 was required
to maximise the immunogenicity of the HIV-v prepar-
ation (data not shown). Montanide ISA-51 is composed
of a light mineral oil and a surfactant system designed to
make a water-in-oil emulsion. It has been demonstrated
to be a very efficient adjuvant, activating the cellular and
the humoral immune response [50,51]. Comparative stud-
ies with calcium phosphate gel and aluminium-based
adjuvants suggest that Montanide ISA-51 is amongst
the safest and most effective adjuvants for synthetic
peptide vaccine formulations [8]. Montanide ISA-51 is
part of the growing number of adjuvant formulations
being developed for human use. In HIV these include
lipopeptide formulations of Nef, Gag and Env derived
peptides or full proteins which have been shown to elicit
sustained T cell responses in clinical trials [52,53].
In our studies, splenocytes from HIV-v immunised
animals secreted higher levels of IFN-γ (p <0.05) than
those from NRP-v immunised animals when cultured
with soluble Vif (2721.3 ± 22.7 vs 446.7 ± 10.6, pg/ml,
mean ± S.E.M) and Rev (2027.5 ± 8.0 vs 976.3 ± 10.5)pitopes
Locationa Length
51 to 80 30
KT 142 to 181 40
69 to 95 27
QGYFPD 81 to 123 43
36 to 67 32
124 to 158 35
255 to 275 21
306 to 326 21
395 to 428 34
32 to 55 24
efined for that protein. The length of the polypeptide is expressed as number
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observed in response to soluble Vpr and Nef polypeptides
in splenocytes from either HIV-v or NRP-v immunised
mice. This may reflect their reduced solubility in cell
culture media, and hence bioavailability, and/or the ab-
sence of strong murine T cell epitopes in their sequences.
In vitro stimulation with soluble antigen is regularly
used to determine overall antigen-specific cellular im-
mune responses. However, because our HLA-A*0201
transgenic mice strain expresses simultaneously Class I
murine MHC and HLA molecules, the assay is unable
to discriminate between T cells reacting to epitopes
complexed to murine MHC and those reacting to epi-
topes complexed to HLA. Moreover, because murine
Class I MHC molecules are more abundant on the cell
membrane of these mice than Class I HLA molecules,
epitopes derived from soluble antigen captured and
processed by APCs in the splenocyte suspension have a
greater likelihood of being complexed with the murine
molecules [49]. To address this problem and to allow us
to identify HIV-v specific Class I HLA restricted T cellA
B
Figure 2 IFN-γ secretion by splenocytes exposed to soluble and trans
mice immunised with HIV-v or NRP-v were exposed in vitro to Vpr (A), Vif (
transfected in syngeneic T1 (T1-Vpr, T1-Vif, T1-Rev and T1-Nef) and allogene
represented as the net increment in IFN-γ production (pg/ml) over the resp
cells (25 ±10 pg/ml for soluble Lysozyme, 316 ±43 pg/ml for T1 cells, and 1
standard positive control to confirm assay validity. A positive response, ind
over the control group’s response with a statistical significance of p < 0.05.
quadruplicate wells. This graph is a representative of three independent exresponses, single polypeptides were also transfected
into syngeneic (HLA-A*0201 bearing) T1 or allogeneic
(HLA-A*0201 non-bearing) JURKAT human cells. Co-
culture of splenocytes from HIV-v or NRP-v immunised
animals with allogeneic Jurkat cells transfected with HIV-v
polypeptides did not induce significant levels of IFN−γ
secretion. However when the same splenocytes were co-
cultured with syngeneic T1 cells transfected with HIV-v
polypeptides, a significant increase (p <0.05) in IFN−γ
secretion (pg/ml, mean ± S.E.M) was detected in the
HIV-v vaccinated animals (HIV-v vs NRP-v immunised
mice: Vpr: 1413.5 ± 43.4 vs 52.8 ± 7.3; Vif: 2027.8 ± 22.2
vs 737.4 ± 39.7; Rev: 329.3 ± 10.5 vs 172.2 ± 40.2; Nef:
1843.8 ± 15.5 vs 391.9 ± 25.7, respectively) (Figure 2).
HLA-A*0201 transgenic mice do not bear any other
HLA and there is no evidence that their CD8+ T cells
would recognize any HIV-v-derived epitopes in the con-
text of other HLAs that they have never encountered
[54]. Therefore, an increased IFN-γ production by trans-
genic splenocytes from HIV-v vaccinated animals when
co-cultured with human syngeneic cells transfected withC
D
fected HIV-v polypeptides. Splenocytes of HLA-A*0201 transgenic
B), Rev (C) and Nef (D) polypeptides as well as polypeptides
ic JURKAT (Ju-Vpr, Ju-Vif, Ju-Rev and Ju-Nef) cells. IFN-γ production is
onse to the negative control antigens Lysozyme or non-transfected
9 ±6 pg/ml for JURKAT cells, average ± SEM). Con A was used as a
icated by an asterisk (*), was defined as an increment of at least 30%
Splenocytes from each individual were assayed separately in
periments.
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interpreted as a response mediated by CD8+ T cells
recognising HIV-v epitopes via HLA-A*0201.
No IL-4 responses were detected against any of the
polypeptides, either soluble or transfected (data not shown).
Since IL-4 antagonises IFN−γ, the lack of an IL-4 response
is again consistent with HIV-v inducing a Th1-like response.Cellular response to HIV-infected human cell lines
Having demonstrated that HIV-v immunised splenocytes
recognise HIV-v derived epitopes in an HLA Class I re-
stricted manner, we wished to determine whether they
were also capable of recognising virus derived epitopes
that are naturally processed and complexed to Class I
HLA molecules in HIV infected human cell lines. For
this purpose, HIV-v and NRP-v splenocyte suspensions
were co-cultured in vitro with syngeneic (T1) and allo-
geneic (H9) human cell lines, either alone or infected
with HIV-1 IIIb, and tested by flow cytometry for IFN−γ
production by CD3 + CD8+ T cells.
In the positive control, stimulation of HIV-v and NRP-v
splenocytes with PMA-Ionomycin (PMA/I) increased
the percentage of IFN-γ producing CD3 +CD8+ T cells
by over 15 fold and the mean IFN-γ produced per cell
by over 200% in both groups (Figure 3). Co-culture of
HIV-infected or non-infected allogeneic human H9 cells
with splenocytes from HIV-v and NRP-v vaccinated
mice did not differ in either the number of IFN-γ produ-
cing CD3+ CD8+ cells or in the mean IFN-γ produced
per cell (Figure 3). Similarly, no differences were ob-
served in splenocytes from the NRP-v group co-cultured
with either healthy or HIV infected syngeneic T1 cells.
In contrast, splenocytes from the HIV-v immunised
group co-cultured with HIV-infected syngeneic T1 cells
experienced a 2-fold increase in the number of CD3+
CD8+ IFN-γ producing cells and a 35% increment in the
mean IFN-γ produced per cell, compared to co-culture
with non-infected cells (Figure 3). The response gener-
ated by HIV-v vaccination at this stage is modest, but
supports the conclusion that HIV-v immunisation can
induce HLA-A*0201 restricted CD3 + CD8+ T cells that
specifically recognise an HIV infected human cell line.
Improvements in this response might be achieved through
optimisation of the dose and the schedule of immunisation.
The slightly higher level of the CD3 + CD8+ back-
ground response observed in both the HIV-v and NRP-v
groups against the non-infected H9 cells compared to
non-infected T1 cells (non-infected H9 vs T1; HIV-v:
4.0% v 2.1%; NRP-v: 3.5% v 2.0%) is not biologically rele-
vant to the virus-specific response elicited by HIV-v
vaccination. This difference may be explained from the
underlying non-antigen specific stimulatory response
triggered by the allogeneic nature of the H9 cells and isconsistent with previous observations reported in the
literature [55].
Antibody response to HIV-v
Antibodies play multiple roles in anti-viral immunity
including virus neutralisation [56], immune complex
phagocytosis [57], complement activation [56,58] and
antibody-dependent cellular cytotoxity (ADCC) [56,59,60].
Antibodies are distributed in serum and the extravascular
space of mucosal tissues [61,62], one of HIV’s primary
routes of entry and hence can play a key role in control-
ling infection and disease. However generation of anti-
HIV antibody responses is delayed until virus latency is
established. Early destruction of B cell generative micro-
environment may be responsible for this delayed antibody
response [63].
Our in silico algorithm does not assess, and the HIV-v
polypeptides were not selected based on B-cell immuno-
genicity. Nonetheless, HIV-v vaccination elicited an IgG
response specific to Vif and Nef polypeptides (Figure 4B
and 4D). Interestingly, the response to the Vif polypep-
tide was higher (still detectable at a 1/1600 serum dilu-
tion, p < 0.05) than that to the Nef polypeptide. No
response against the Vpr or Rev polypeptides was ob-
served (Figure 4A and 4C). Further analysis of the Vif
and Nef responses determined that the IgG2c compo-
nent is dominant over the IgG1 (Figure 4E and 4F).
HIV patients generally produce antibodies against Vpr
and Rev [64,65] and the lack of response in our study
may reflect the absence of B cell epitopes in the selected
Vpr and Rev regions. The isotype of the IgG response
was biased towards the IgG2c subclass, which is func-
tionally equivalent to IgG2a in the genetic background
of the transgenic mice used [66]. This subclass is associ-
ated with IFN-γ production [67] which is consistent with
our assertion that HIV-v immunisation triggers a Th1
immune response.
HIV-v specific antibodies induce lysis of HIV-infected T1
cells through complement activation
The trend in HIV vaccine development has focused for
many years on the development of an antibody response
characterised by the generation of neutralising antibodies
(NAbs) directed to viral capsid components. These NAbs
naturally appear months after infection and are not able to
neutralise viral strains divergent from the infecting strain
[68]. Recent efforts to develop more broadly neutralising
antibodies (bNAbs) have proven difficult [69]. A different
strategy is to develop a non-neutralising antibody re-
sponses that are directed not to virion components (e.g.
capsid proteins), but to viral proteins that are associated
to the cellular membrane of infected cells. These anti-
bodies would then be able to trigger either ADCC via
the Fc receptors on NK and Macrophages of effector
Figure 3 IFN-γ production by CD3+ CD8+ cells in response to co-culture with HIV-infected human cells. IFN-γ responses of primary splenocyte
cultures from HLA-A*0201 transgenic mice immunised with either HIV-v or NRP-v following co-culture with human syngeneic (T1) or allogeneic (H9) cells
alone or infected with the HIV-1 IIIB strain were measured by flow cytometry. Panel A indicates the gating strategy applied to the analysis. Non viable
cells and target cells were gated out prior measuring IFN-γ in CD3 + CD8+ cells. Panels B to D show the number of IFN-γ producing cells (events Y axis)
vs the intensity of IFN-γ produced (X axis). The marker (M1) corresponds to the range of signal considered as a positive response. The response’s
Geometric Mean (GM) and coefficient of variation (CV) as well as the % of events within M1 are also provided. Panel B corresponds to splenocytes (SPN)
from NRP-v and HIV-v immunized groups untreated or treated with PMA + Ionomycin (PMA/I). Panel C corresponds to splenocytes co-cultured with
allogeneic H9 alone or infected with IIIb HIV-1. Panel D corresponds to splenocytes co-cultured with syngeneic T1 cells alone or infected with IIIb HIV-1.



























































































































Figure 4 Total Ig and IgG isotype responses to the HIV-v polypeptide components. Responses were measured by ELISA in sera from HIV-v
or NRP-v immunised HLA-A*0201 transgenic mice. Total Ig responses to the Vpr (A), Vif (B), Rev (C) and Nef (D) peptides are represented as
average ng/ml (± SEM) versus sera dilution. IgG2c (E) and IgG1 (F) responses to Vif and Nef peptides were quantified in a 1:200 serum dilution.
A positive response, indicated by an asterisk (*) was defined as an increment of at least 100% over the background response with a statistical
significance of p < 0.05.
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outcome would be the destruction of the HIV-infected
cells [70-72].
HIV-v targets primarily non-capsid proteins and thus
the antibody response it elicits is not expected to haveneutralisation potential. Nonetheless, we wished to estab-
lish whether the IgG response generated against HIV-v
could mediate a significant anti-viral effector mechanism.
For that purpose, NRP-v and HIV-v immunised sera were
tested for their ability to activate complement and lyse
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or clade A field isolate UG/92/029. Figure 5 shows that
sera from HIV-v immunised animals induced a signifi-
cantly higher level of lysis of HIV infected T1 cells than
sera from NRP-v immunised animals (72.8% ± 17.8 vs
23.9% ± 1.1 for UG/92/029 infected cells, and 85.7% ±
8.2 vs 44.8% ± 1.0 for IIIB infected cells).
The different levels of cell lysis induced by the NRP-v
sera against cells infected with the two test strains of
HIV-1 do not detract from the clear anti-viral effector
function of the HIV-v specific sera, but they do reflect
two important features of the assay. Firstly, the baseline
lysis (0%) for both the IIIB and the UG/92/029 infected
T1 cells is defined by non-infected T1 cells in the pres-
ence of complement. Viral antigens on the surface of
infected cells are known to spontaneously activate the
alternative complement pathway, which is antibody in-
dependent [73]. As a result, the observed increase over
baseline in the lysis caused by NRP-v is probably due to
a nonspecific release of LDH enzyme during the assay.
Secondly, in preparation for this assay, T1 cells were
infected with the different viral strains and only used as
targets when intracellular HIV p24 expression was max-
imal. For strain IIIB that corresponded to 2 days post-
infection (42% cellular viability) whilst for strain UG/92/
029 it was 10 days post-infection (61.2% cellular viabil-
ity). As the assay measures release on the medium of a
strict intracellular enzyme (LDH), which is also known
to leak through damaged membranes, the higher non-
specific response (i.e. against NRP-v) observed against
the IIIb infected T1 cells (44.8%) is consistent and en-
tirely correlates with its reduced cell viability (42%) at














Figure 5 Complement mediated cell lysis of HIV-1 infected human ce
NRP-v immunised mice were diluted 1/100 in PBS, combined with rabbit c
isolate UG-29-029 (clade A) or laboratory strain IIIB. The percentage of cell
cells in the presence of complement without sera (0%) and the LDH releas
response, indicated by an asterisk (*), was defined as an increment of lysis
control (NRP-v) sera and with a statistical significance of p < 0.05. RepresenConclusion
In summary, immunisation with HIV-v, an equimolar
formulation of four synthetic polypeptides covering con-
served immunogenic regions in Vif, Vpr, Nef and Rev in
Montanide ISA-51, induces specific CD8+ T cell and
IgG responses that are able to recognise and kill a hu-
man cell line infected with either laboratory adapted or
primary isolate strains of the HIV-1 virus. Based on our
results, we believe HIV-v constitutes a promising HIV
vaccine and/or immunotherapeutic candidate. Moreover,
the cytotoxic effect observed for the antibodies produced
against Nef and Vif peptides highlights their potential
value for the development of passive immunotherapeutic
agents (e.g. MAb polytherapy) to treat HIV infection.
Methods
Animals, cell lines and virus
Transgenic homozygous C57BL/6-TgN(HLA-A2.1)1Enge
mice, male: female ratio 1:1, aged 7–10 weeks, weighing
between 22-23 g (males) and 18-21 g (females) were
used. Transgene carrier status and expression were mon-
itored and confirmed every 6 months by qPCR and RT-
PCR, respectively at Charles River, UK.
All cell lines were obtained from ATCC. T1 (HLA-
A*0201-bearing) and H9 (non-HLA-A*0201-bearing) hu-
man cell lines were maintained in IMDM (Sigma) whilst
JURKAT (non- HLA-A*0201-bearing) and splenocytes were
kept in RPMI-1640 (Sigma). Media was supplemented
with 50 IU/50 μg/ml of penicillin/streptomycin (Sigma)
and 10% FCS (20% for H9 cells)(Sigma).
HIV-1 strain IIIB or field isolate UG/92/029 (Clade A)
(NIBSC) were used to naturally infect T1 and H9 cells.
Infection was monitored with intracellular p24 Gag level.T1 + IIIB
-v HIV-v
lls measured as LDH release. Heat inactivated sera from HIV-v and
omplement and added to cultures of T1 cells infected with HIV-1 field
lysis was defined between the level of LDH release of non-infected T1
ed after lysing the same cells with Triton X-100 (100%). A positive
of at least 50% over that of HIV-1 infected cells in the presence of
ted are the averages of percentage cell lysis ± SEM.
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infected cells (42% cellular viability) vs 10 days in UG/
92/029 infected cells (61.2% cellular viability).
Ethics
All animal experimentation was carried out by third par-
ties. Southern Research Institute (United States) carried
out the work according to IACUC protocols (US) under
ethical approval granted to projects 12761.01, 12595.01
and 12595.02.
The experiments carried out at Keele University
(United Kingdom) and Harlan UK were done under
project licenses PPL 40/2411 and PPL 60/3418, respect-
ively, following the European Directive EC 86/609
and her majesty’s Home Office regulations under the
Animals (Scientific Procedures) Act 1986.
Identification of conserved immunoreactive regions
Conserved regions in HIV were identified by analysing
with CLUSTALW [74,75] all HIV-1 and −2 isolates
sequences available at the National Centre for Bio-
technology Information (NCBI) Taxonomy database
(January 2006) [76]. The aim of the analysis was to
determine the existence and location of short highly
conserved domains within the HIV proteome and not
the overall degree of conservation of individual proteins.
Regions of 20 to 50 aa in the consensus sequences where
every consecutive amino acid was present in ≥70% of the
isolate population were considered conserved. The identi-
fied consensus sequences were analysed for the presence
of reactive T cell epitopes for mouse MHC H-2kb and
HLA *A-02, *A-24, *B-24,*B-27 and *B35 alleles using a
proprietary algorithm (PepTcell Ltd). The algorithm iden-
tifies and categorises T cell epitopes within a protein based
on analysis of the structural affinity of a peptide for a given
MHC/HLA allele and the reactivity of this complex to T
cells. The final selection of conserved polyepitope T-cell
reactive fragments in the HIV population was based
on four criteria: 1) length between 20–50 aa long, 2)
containing at least five reactive epitopes, 3) sharing no
similarity to other murine/human protein sequences,
and 4) feasibility of F-moc synthesis. The final success-
ful candidates were synthesised by Fmoc chemistry at
BACHEM (Switzerland).
Immunisations
HIV-v is an equimolar mix of four multi-epitope syn-
thetic polypeptides. NRP-v is an equimolar mix of multi-
epitope non-HIV derived polypeptides. On Day 1 mice
were immunised subcutaneously at the base of the tail
(200 μl) with HIV-v or NRP-v (10 nmol of each peptide,
optimal for T cell response, or 5 nmol of each peptide,
optimal for antibody response) in PBS emulsified 1:1
with adjuvant Montanide ISA-51 (Seppic). A total of 12animals (6 males and 6 females) per group were immunised.
All animals received a booster immunisation (same doses)
on day 15 and were culled on day 21 when spleens and
sera were collected. All experimental work was carried out
in accordance with the Scientific Procedures Act (1986)
and IACUC regulations.
Cytokine ELISA from supernatants of splenocyte cultures
Splenocyte suspensions from each single animal were
prepared as previously described [29], seeded at 4 × 105
cells/well in 96-well plates (BD) and cultured in quadru-
plicates for 96 h with either soluble treatments (i.e. media,
5 ug/ml of NRP-v, 5 ug/ml of each individual HIV-v poly-
peptide, 5 ug/ml Concanavalin A (Sigma), 1ug/ml Lyso-
zyme (Sigma)), or 4×104 cells (T1 or Jurkat) either alone
or transfected with each individual HIV-v polypeptide.
Transfections were performed using Lipofectin (Invitrogen)
following manufacturer’s instructions. IFN-γ and IL-4
responses were determined by ELISA analysis of the
supernatants according to the manufacturer’s instruc-
tions (OptEIA kits, BD). This experiment was performed
three times.
Intracellular cytokine staining
Splenocyte suspensions were seeded at 4×106 cells/ml and
challenged with either 10 ng/ml PMA+ 1 μg/ml Ionomycin
(Sigma) or 4×105 cells/ml of Mitomycin C-inactivated T1
(syngeneic) or H9 (allogeneic) cells, either alone or
infected with HIV-1 IIIB. Following 15 h incubation at
37°C, GolgiPlug (BD) was added and plates were incu-
bated for a further 4 h. Supernatants were removed, a
FcR block performed and the cells washed and stained
with anti-mouse CD3 FITC-conjugated (clone 145-2C11)
and anti-mouse CD8 PerCP-Cy5.5-conjugated (clone
53–6.7) antibodies (BD) for 15 min. After washing, cells
were fixed for 20 min (Cytofix/Cytoperm, BD) and
washed again. After permeabilisation for 20 min with
Perm wash buffer (BD), cells were washed and anti-
mouse IFN-γ APC-conjugated (clone XMG1.2, BD) anti-
body was added. After 20 min incubation, cells were
washed and resuspended in Cytofix buffer (BD). After
overnight storage at 4°C cells were analysed with a
FACScalibur flow cytometer (BD). One million events
were acquired per reaction and data was processed
using WinMDI 2.9 software. Non-viable cells were
gated out in a FSC/SSC. Viable cells were plotted in a
CD3vsCD8 dot plot to separate the CD3+CD8+ splenocytes
from the HIV-infected target cells. Intracellular IFN-γ was
then measured in the CD3 +CD8+ splenocyte population.
Antibody ELISA
ELISA 96-well plates were coated overnight at +4°C
with 2 μM of single HIV-v polypeptides in PBS (Sigma).
Plates were washed with PBS + 0.05% Tween 20 (Sigma)
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(Sigma) in PBS. After washing with PBS-T, test sera
samples were added. Following 2 h incubation, plates
were washed with PBS-T and either HRP-conjugated
goat anti-mouse-Ig (Sigma), HRP-goat anti-mouse IgG1
(AbD Serotec) or HRP-rat anti-mouse IgG2a/c (BD Bio-
sciences) was added. After 1h incubation, plates were
washed with PBS-T and TMB substrate (Sigma) was
added. The reaction was stopped with 0.5M H2SO4 and
absorbance was read at 450 nm. Antibody concentra-
tions were quantified against purified total Ig (Sigma),
IgG2c (BD Biosciences) and IgG1 (AbD Serotec) stan-
dards. Sera samples from each individual were tested
separately in triplicates at various dilutions (1:100, 1:200,
1:400, 1:800 and 1:1600).
Antibody-activation of complement
HIV-1 IIIb or UG/92/029 (Clade A) infected T1 cells were
seeded at 6×103 cells/well in flat bottom 96-well plates
together with heat inactivated test sera (diluted 1/100 in
PBS) and baby rabbit complement (AbD Serotec). After
2 h incubation, cell lysis (Experimental Release) was
measured using the LDH based CytoTox 96WNon-
Radioactive Cytotoxicity Assay according to manufac-
turer’s instructions (Promega). The dynamic range of
the assay was determined using as minimum LDH
release (MIN) non-infected T1 cells incubated with baby
rabbit complement in PBS without sera and as maximum
LDH release (MAX) cells lysed with Triton X-100.
The percentage of Specific Immune Lysis (% SIL) was
calculated using the following formula:
%SIL ¼ 100  ExperimentalReleaseMINRelease
MaxReleaseMINRelease
Statistical analysis
Statistically significant increases in the immune responses
to antigens between the HIV-v and NRP-vaccinated ani-
mals were established by non-parametric Mann–Whitney
analysis. Differences were considered statistically signifi-
cant if the p value was <0.05.
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